The most advanced is Staccato loxapine, which is designed to treat agitation in patients with schizophrenia and bipolar disorder, and is also being tested against Parkinson's disease psychosis, schizophrenia, and Alzheimer's disease psychosis.    From Wordnik.com.  [SFGate: Top News Stories] Reference

The IND for Staccato loxapine was filed with the FDA in August 2005.    From Wordnik.com.  [Health News from Medical News Today] Reference

Though it has a-- appears to have a higher side effect profile than loxapine.    From Wordnik.com.  [Biotech Sector and Stocks Analysis from Seeking Alpha] Reference

The NDA for the inhalation delivered Staccato loxapine was filed with the FDA in.    From Wordnik.com.  [SeekingAlpha.com: Home Page] Reference

(NYSE: BVF), to develop and commercialize AZ-004 (Staccato® loxapine) in the U.S. and.    From Wordnik.com.  [THE MEDICAL NEWS] Reference

But we collectively have the and loxapine that slowing these restrictions can convert benefit.    From Wordnik.com.  [Wii-volution] Reference

I think having the data from the take home study with loxapine will be an important consideration.    From Wordnik.com.  [SeekingAlpha.com: Home Page] Reference

Staccato loxapine rapidly delivered drug into the blood stream through the deep lung in a unique, non-invasive manner.    From Wordnik.com.  [THE MEDICAL NEWS] Reference

However, the real news for this company is their pending FDA New Drug Application Decision for Staccato loxapine (AZ-004).    From Wordnik.com.  [SeekingAlpha.com: Home Page] Reference

(Staccato loxapine) that is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients.    From Wordnik.com.  [Health News from Medical News Today] Reference

"It is splendid that Alexza has reached its first NDA so quickly and is on the doorstep of its first Staccato-based product, Staccato loxapine.".    From Wordnik.com.  [Health News from Medical News Today] Reference

AZ-004, Staccato loxapine, again we're developing AZ-004 for the treatment of acute agitation in patients with schizophrenia or bipolar disorder.    From Wordnik.com.  [Biotech Sector and Stocks Analysis from Seeking Alpha] Reference

AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients.    From Wordnik.com. Reference

AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the rapid treatment of agitation in schizophrenic or bipolar disorder patients.    From Wordnik.com.  [Health News from Medical News Today] Reference

AZ-104 is the combination of Alexza's proprietary Staccato system with loxapine, a drug belonging to the class of compounds known as dopamine receptor antagonists.    From Wordnik.com.  [Health News from Medical News Today] Reference

And we have apples-to-apples comparison of loxapine and prochlorperazine in an in-clinic setting, but we don't have apples-to-apples comparison in an outpatient setting.    From Wordnik.com.  [Biotech Sector and Stocks Analysis from Seeking Alpha] Reference

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it has initiated a Phase 2b clinical trial with AZ-104 (Staccato loxapine) in patients with migraine headaches.    From Wordnik.com.  [Health News from Medical News Today] Reference

Alexza has completed an end-of-Phase 2 meeting with the FDA for AZ-001 (Staccato prochlorperazine) and has completed two Phase 2 studies with AZ-104 (Staccato loxapine, low-dose).    From Wordnik.com.  [The Earth Times Online Newspaper] Reference

AZ-004 is an anti-agitation therapeutic that combines Alexza's proprietary Staccato system with loxapine, a drug belonging to the class of compounds known generally as antipsychotics.    From Wordnik.com.  [Health News from Medical News Today] Reference

AZ-104 is a lower-dose version of AZ-004 (Staccato loxapine), Alexza's lead product candidate that is in late Phase 3 clinical development for the acute treatment of agitation in patients with schizophrenia or bipolar disorder.    From Wordnik.com.  [Health News from Medical News Today] Reference

(Nasdaq: ALXA) announced today that it has established a collaboration with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation (NYSE: BVF), to develop and commercialize AZ-004 (Staccato® loxapine) in the U.S. and Canada.    From Wordnik.com.  [The Earth Times Online Newspaper] Reference

And then talk to me about the complications potentially of trying to partner loxapine, when you have also got low-dose loxapine for another indication and then you have that somewhat tied to prochlorperazine because you are talking about partnering the whole migraine program.    From Wordnik.com.  [Biotech Sector and Stocks Analysis from Seeking Alpha] Reference

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it has submitted its New Drug Application (NDA) for Staccato® loxapine (AZ-004) to the US Food and Drug Administration.    From Wordnik.com.  [Health News from Medical News Today] Reference

"In clinical studies conducted by Alexza, Staccato loxapine rapidly delivered drug into the blood stream through the deep lung in a unique, non-invasive manner.    From Wordnik.com.  [The Earth Times Online Newspaper] Reference

Staccato loxapine in December 2009.    From Wordnik.com.  [THE MEDICAL NEWS] Reference

(NDA) for Staccato loxapine in December 2009.    From Wordnik.com.  [The Earth Times Online Newspaper] Reference

AZ-004 (Staccato loxapine).    From Wordnik.com. Reference

(Staccato loxapine, low-dose).    From Wordnik.com.  [Health News from Medical News Today] Reference

About AZ-004 (Staccato loxapine).    From Wordnik.com.  [Health News from Medical News Today] Reference

About AZ-104 (Staccato loxapine).    From Wordnik.com.  [Health News from Medical News Today] Reference

Moving to AZ-104, Staccato loxapine.    From Wordnik.com.  [Biotech Sector and Stocks Analysis from Seeking Alpha] Reference

loxapine) from Biovail Laboratories International SRL ("BLS"), a wholly-owned subsidiary of.    From Wordnik.com.  [Alexza Pharmaceuticals Reacquires U.S. and Canadian Rights for AZ-004 (Staccato® Loxapine) - Yahoo! Finance] Reference

Daxolin loxapine, 292.    From Wordnik.com.  [Shouldn’t I Be Happy?] Reference

Staccato loxapine.    From Wordnik.com.  [SeekingAlpha.com: Home Page] Reference

Staccato® loxapine).    From Wordnik.com.  [RedOrbit News - Technology] Reference

Staccato loxapine, low-dose).    From Wordnik.com. Reference

AZ-004 (Staccato loxapine).    From Wordnik.com.  [RedOrbit News - Technology] Reference